Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

BACKGROUND: Demethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1. We hypothesized that azacitidine and oxaliplatin combination therapy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Epigenetics
Hauptverfasser: Tsimberidou, Apostolia M, Said, Rabih, Culotta, Kirk, Wistuba, Ignacio, Jelinek, Jaroslav, Fu, Siqing, Falchook, Gerald, Naing, Aung, Piha-Paul, Sarina, Zinner, Ralph, Siddik, Zahid H, He, Guangan, Hess, Kenneth, Stewart, David J, Kurzrock, Razelle, Issa, Jean-Pierre J
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2015
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4371799/
https://ncbi.nlm.nih.gov/pubmed/25806091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-015-0065-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge